Latest News & Upcoming Events
February is National Age-Related Macular Degeneration (AMD) and Low Vision Month. This disease is the leading cause of blindness, and its prevalence is expected to soar as the world’s population ages, leading to an overwhelming projected demand for AMD care by 2050.
A roundtable discussion between leading optometrists led by Dr. Greg Caldwell summarizing current understanding of early stages of AMD, the link to impaired dark adaptation and the benefits of implementing dark adaptation testing into optometric practice.
Dr. Julie Rodman explains that from a pathophysiological standpoint AMD is AMD—regardless of stage or how long the disease has progressed. In this article, she lists the treatments that should be offered to patients— even at the earliest stages of AMD.
Dr. Timothy Earley provides his insights on why having a quantifiable measure (RI) and a highly specific and sensitive diagnostic tool have completely changed his approach to AMD.
Dr. Karpecki and Dr. Lowe evaluate both the structure and function of the retina to help diagnose AMD and monitor disease progression.
Here’s a snapshot of how fellow eye care colleagues added new AMD protocols in their practices to make implementation easier from day one.
Here’s what faculty from three top schools have to say about dark adaptation in their programs today.
Dr. Gary Kirman, one of the earliest adopters of dark adaptation testing in optometric practice, reflects on his role in helping to create an elevated standard of care for practices everywhere.
Dr. Glenn Corbin, one of the earliest adopters of dark adaptation testing in optometric practice, explains how using both structural and functional testing removes the guesswork out of AMD diagnosis and monitoring.
Dr. Greg Jackson takes a moment to reminisce about the shift that occurred between 1998 and 2021 that brought dark adaptation testing into mainstream optometry.